loading page

Exploratory Analysis of the Economically Justifiable Price of Nirsevimab for Healthy Late-Preterm and Term Infants in Colombia
  • Jefferson Buendia,
  • Ranniery Acuna-Cordero,
  • Carlos Rodriguez-Martinez
Jefferson Buendia
Universidad de Antioquia Facultad de Medicina

Corresponding Author:[email protected]

Author Profile
Ranniery Acuna-Cordero
Universidad Militar Nueva Granada
Author Profile
Carlos Rodriguez-Martinez
Universidad Nacional de Colombia Facultad de Medicina
Author Profile


Introduction. Respiratory syncytial virus infection is the leading cause of lower respiratory infection globally. Recently, nirsevimab has been approved to prevent RSV infection. This study explores the economically justifiable price of nirsevimab for preventing RSV infection in Colombia’s children under one year of age. Materials and methods. A static model was developed using the decision tree microsimulation to estimate the quality-adjusted costs and life years of two interventions: a single intramuscular dose of nirsevimab versus not applying nirsevimab. This analysis was made during a time horizon of 1 year and from a societal perspective. Results The annual savings in Colombia associated with this cost per dose ranged from U$ 2.5 to 4.1 million. Based on thresholds of U$4828, U$ 5128, and U$19 992 per QALY evaluated in this study, we established economically justifiable drug acquisition prices of U$ 21.88, U$ 25.04, and U$ 44.02 per dose of nirsevimab. Conclusion the economically justifiable cost for nirsevimab in Colombia is between U$21 to U$44 per dose, depending on the WTP used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.
04 Oct 2023Submitted to Pediatric Pulmonology
04 Oct 2023Assigned to Editor
04 Oct 2023Submission Checks Completed
04 Oct 2023Review(s) Completed, Editorial Evaluation Pending
15 Oct 2023Reviewer(s) Assigned